VivoSeq
Oncology

Primary Breast Cancer

3

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Primary Breast Cancer is an early-stage landscape with 3 programs across 1 company. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd.. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSAntibody–drug conjugate133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 60% of 5 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Enrolling by invitation2 · 40%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Active, not recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT06126640·1,615 enrolled
SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Using Iodine -123-labelled Designed Ankyrin Repeat Proteins HE3-G3 ([123I] I-(HE)3-G3)
Completed·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 1·NCT05923177·10 enrolled
SPECT/CT Imaging of Gastrin-releasing Peptide Receptor Expression in Breast Cancer With Different Estrogen Receptor Expression Using Technetium-99m-labelled DB8 [99mTc]Tc-DB8
Enrolling by invitation·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 2·NCT07275463·40 enrolled
SPECT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Using Technetium-99m-labelled Designed Ankyrin Repeat Proteins HE3-G3 (99mTc-HE3-G3)
Completed·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 1·NCT04277338·30 enrolled
SPECT/CT Imaging of Different Types of HER2 Expression in Breast Cancer Using Technetium-99m-labelled Affibody [99mTc]Tc -ZHER2:4107
Enrolling by invitation·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 2·NCT07292571·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)